In an industry governed by strict compliance, razor-thin timelines, and constant paradigm shifts, where do senior regulatory leaders go to have honest, peer-to-peer conversations?
If you look at the typical industry calendar, it’s flooded with massive, multi-track conferences. You sit in crowded auditoriums, listen to rehearsed slide decks, and walk through expo halls dodging aggressive vendor sales pitches. While those events have their place, they often miss the mark on what leaders actually need: a place to drop the corporate shield, talk about real-world friction points, and benchmark against peers in the trenches.
That is exactly why the Boston Regulatory Affairs Group (BRAG) was founded.
BRAG isn’t just another networking group. It is an exclusive, closed-door community designed specifically by and for senior regulatory executives. Here is a look behind the curtain at what makes this community the most valuable room in the industry.
A Strict “Safe Harbor” Environment
The number one rule of BRAG? No vendor pitches. BioPoint intentionally protect the space so that Vice Presidents, SVPs, and Chiefs of Regulatory Affairs can speak with absolute candor. Whether we are discussing health authority shifts or the operational realities of a new submission, members can share what is actually working (and just as importantly, what isn’t) without being sold a software platform or a consulting package five minutes later.
Tackling “Utility vs. Reality”
We don’t do high-level fluff. Our sessions are built around the immediate friction points impacting drug development pipelines. For example, as the market hyper-focuses on the promises of Regulatory AI, BRAG is leading the charge on breaking down the topic into pragmatic, digestible tracks:
-
-
- The Individual Lens: How professionals are utilizing day-to-day “life hacks” on their laptops right now (like gap analysis and commitment tracking) to work faster.
- The Enterprise Lens: How companies are navigating multi-million dollar infrastructure investments, validation roadblocks, and defending AI-generated data under intense FDA scrutiny.
-
By looking at the distinct gap between vendor promises and submission reality, our members walk away with actionable frameworks they can immediately deploy within their own organizations, whether they are managing a lean, small-cap biotech budget or scaling a global, large-cap pharma portfolio.
Big Pharma Power Meets Small Biotech Agility
One of the most unique dynamics of a BRAG roundtable is the cross-pollination of company sizes. Smaller biotechs get to safely benchmark their frameworks against the robust, highly-resourced infrastructures of large-cap market leaders. Meanwhile, larger organizations gain insight into the agile, creative problem-solving happening on the boutique side of the sector. Everyone leaves the room smarter than when they walked in.
Looking Ahead: Driving the Industry Forward
As a community, we are expanding our footprint—bringing our signature collaborative format across the coast to our sister organization, CORA (California Organization for Regulatory Affairs) in San Francisco, while continuing to anchor premier briefings right here in Boston.
Regulatory affairs is changing faster than ever. You shouldn’t have to navigate the horizon alone.
Join the Conversation
Are you a senior regulatory leader looking for a true peer community? Follow our page for upcoming summer session announcements, or reach out directly to learn more about securing an invitation to our next private roundtable.